Cat. #153512
Anti-CD19 [4G7]
Cat. #: 153512
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: CD19
Class: Monoclonal
Application: ELISA ; FACS ; IHC ; WB
Reactivity: Human
Host: Mouse
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Clonegene LLC
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-CD19 [4G7]
- Alternate name: B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12
- Clone: 4G7
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Mouse
- Application: ELISA ; FACS ; IHC ; WB
- Description: CD19 assembles with the antigen receptor of B-lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 is a hallmark of B-cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B-cell lymphomas.Since 2011 treatments targeting CD19 have begun to enter trials. Most current experimental anti-CD19 drugs in development work by exploiting the presence of CD19 to direct treatment specifically towards B-cell cancers. However, it is now emerging that the protein plays an active role in driving the growth of these cancers, most intriguingly by stabilizing the concentrations of the myc oncoprotein. This suggests that CD19 and its downstream signaling may be a more attractive therapeutic target than originally thought. CD19 has also been implicated in autoimmune diseases and may be a useful treatment target.
- Immunogen: CD19
- Isotype: IgG1
Target Details
- Target: CD19
- Target background: CD19 assembles with the antigen receptor of B-lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 is a hallmark of B-cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B-cell lymphomas.Since 2011 treatments targeting CD19 have begun to enter trials. Most current experimental anti-CD19 drugs in development work by exploiting the presence of CD19 to direct treatment specifically towards B-cell cancers. However, it is now emerging that the protein plays an active role in driving the growth of these cancers, most intriguingly by stabilizing the concentrations of the myc oncoprotein. This suggests that CD19 and its downstream signaling may be a more attractive therapeutic target than originally thought. CD19 has also been implicated in autoimmune diseases and may be a useful treatment target.
Applications
- Application: ELISA ; FACS ; IHC ; WB
Handling
- Format: Liquid
- Unit size: 100 ug
- Shipping conditions: Shipping at 4° C
